Foundation-Directed Therapeutic
Development in Huntington’s Disease
- Publication date
- Publisher
Abstract
Huntington’s disease (HD)
is an autosomal dominant neurodegenerative disease that devastates
patients and their families. It is caused by expansion of the CAG
repeat in the huntingtin gene (<i>HTT</i>) and characterized
pathologically by the loss of pyramidal neurons in several cortical
areas, striatal medium spiny neurons, and hypothalamic neurons. Clinically,
a distinguishing feature of the disease is uncontrolled involuntary
movements (chorea) accompanied by progressive cognitive and psychiatric
impairment. Currently there are no effective disease-modifying treatments
for HD, although antidepressant and antipsychotic medications are
typically utilized to manage HD symptoms, in addition to the only
approved drug for the treatment of chorea in HD, tetrabenazine (TBZ).
CHDI is a not-for-profit organization focused solely on HD. Herein
we describe our foundation-directed therapeutic development efforts
highlighting our collaborations and internal programs that are in
various stages of development